10-09-2021, 09:46 AM
But while it may appear that the majority of breakthrough infections involved Sinovac takers, Domingo explained it was likely because that brand was the most widely used in the country.
The FDA chief, who himself received a Sinovac jab to kick-off the national rollout program in March, said there was not enough data to determine any reduction in the Chinese vaccine’s effectiveness.
“Out of six to seven million vaccinated, breakthrough infections and mortalities remain very low. Five months later, it’s not convincing that there has been any waning,” he added.
https://newsinfo.inquirer.net/1486063/fd...c-efficacy
The FDA chief, who himself received a Sinovac jab to kick-off the national rollout program in March, said there was not enough data to determine any reduction in the Chinese vaccine’s effectiveness.
“Out of six to seven million vaccinated, breakthrough infections and mortalities remain very low. Five months later, it’s not convincing that there has been any waning,” he added.
https://newsinfo.inquirer.net/1486063/fd...c-efficacy